Founders Capital Management increased its stake in Pfizer, Inc. (NYSE:PFE) by 0.9% during the second quarter, Holdings Channel reports. The institutional investor owned 53,561 shares of the biopharmaceutical company’s stock after buying an additional 475 shares during the period. Pfizer makes up 1.6% of Founders Capital Management’s investment portfolio, making the stock its 26th largest position. Founders Capital Management’s holdings in Pfizer were worth $1,799,000 at the end of the most recent quarter.
Several other large investors also recently modified their holdings of the company. Highland Capital Management LLC increased its stake in shares of Pfizer by 0.5% in the second quarter. Highland Capital Management LLC now owns 343,096 shares of the biopharmaceutical company’s stock valued at $11,525,000 after buying an additional 1,815 shares in the last quarter. BTIM Corp. increased its stake in shares of Pfizer by 3.0% in the second quarter. BTIM Corp. now owns 92,243 shares of the biopharmaceutical company’s stock valued at $3,098,000 after buying an additional 2,646 shares in the last quarter. Bedrijfstakpensioenfonds Voor DE Media PNO increased its stake in shares of Pfizer by 362.8% in the second quarter. Bedrijfstakpensioenfonds Voor DE Media PNO now owns 147,186 shares of the biopharmaceutical company’s stock valued at $4,944,000 after buying an additional 115,386 shares in the last quarter. Hengehold Capital Management LLC increased its stake in shares of Pfizer by 2.6% in the second quarter. Hengehold Capital Management LLC now owns 71,041 shares of the biopharmaceutical company’s stock valued at $2,386,000 after buying an additional 1,785 shares in the last quarter. Finally, Augustine Asset Management Inc. increased its stake in shares of Pfizer by 8.0% in the second quarter. Augustine Asset Management Inc. now owns 19,421 shares of the biopharmaceutical company’s stock valued at $652,000 after buying an additional 1,441 shares in the last quarter. 69.94% of the stock is owned by hedge funds and other institutional investors.
Pfizer, Inc. (NYSE PFE) traded up 0.03% during mid-day trading on Wednesday, hitting $33.39. The company had a trading volume of 4,531,182 shares. The company’s 50 day moving average price is $33.36 and its 200-day moving average price is $33.37. Pfizer, Inc. has a one year low of $29.83 and a one year high of $35.38. The company has a market cap of $199.27 billion, a PE ratio of 24.43 and a beta of 1.00.
Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.65 by $0.02. The company had revenue of $12.90 billion for the quarter, compared to analyst estimates of $13.08 billion. Pfizer had a return on equity of 24.51% and a net margin of 15.84%. Pfizer’s revenue for the quarter was down 1.9% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.64 earnings per share. Equities research analysts anticipate that Pfizer, Inc. will post $2.56 EPS for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Friday, September 1st. Stockholders of record on Friday, August 4th will be given a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a dividend yield of 3.83%. The ex-dividend date is Wednesday, August 2nd. Pfizer’s dividend payout ratio (DPR) is presently 94.12%.
PFE has been the subject of several research analyst reports. Berenberg Bank reiterated a “hold” rating and issued a $36.00 price objective (down previously from $39.00) on shares of Pfizer in a research report on Tuesday. Cowen and Company set a $43.00 price objective on Pfizer and gave the stock a “buy” rating in a research report on Monday. BidaskClub upgraded Pfizer from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 5th. Jefferies Group LLC set a $35.00 price objective on Pfizer and gave the stock a “neutral” rating in a research report on Wednesday, August 2nd. Finally, BMO Capital Markets upgraded Pfizer from a “market perform” rating to an “outperform” rating and increased their price objective for the stock from $33.00 to $37.00 in a research report on Wednesday, August 2nd. Two analysts have rated the stock with a sell rating, eleven have given a hold rating and ten have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average target price of $37.61.
In other news, CEO Ian C. Read sold 96,950 shares of the business’s stock in a transaction on Friday, August 4th. The stock was sold at an average price of $34.00, for a total transaction of $3,296,300.00. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Alexander R. Mackenzie sold 15,000 shares of the business’s stock in a transaction on Monday, August 7th. The stock was sold at an average price of $33.50, for a total value of $502,500.00. Following the sale, the insider now directly owns 151,474 shares in the company, valued at $5,074,379. The disclosure for this sale can be found here. 0.06% of the stock is owned by insiders.
About Pfizer
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer, Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
